🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

China Medical University, China clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with China Medical University, China as lead sponsor. Synced 26 Sep 2026
14Current trials
10Recruiting now
2Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

China Medical University, China is the lead sponsor of 14 current clinical trials in our China register. 10 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Tislelizumab and Anlotinib. The most-studied condition is Small Cell Lung Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1071%
  • Not yet open429%

Trials by phase

  • Not applicable857%
  • Phase 2321%
  • Phase 4214%
  • Phase 117%
01

Clinical trials sponsored by China Medical University, China

14 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study on the Pathogenesis and Reversal Strategies of Cancer Cachexia Based on Multi-Omics
NCT07519837 · ClinicalTrials.gov ↗ · Cachexia; Cancer; Sarcopenia
Not applicable Recruiting 2026-03 China
Polypills Approach for Multiple Cardiovascular Risk Factors
NCT07679828 · ClinicalTrials.gov ↗ · Hypertension, Dyslipidemia, Diabetes
Not applicable Recruiting 2026-07 China
Binaural Beats for Cognitive Function in Older Adults With Mild Cognitive Impairment in Nursing Homes
NCT07735910 · ClinicalTrials.gov ↗ · Mild Cognitive Impairment, Cognitive Function
Not applicable Recruiting 2026-06 China
A Clinical Study Evaluating the Safety and Efficacy of Anti-HER2-CAR-T Cells Injection in Patients With Solid Tumors
NCT06101082 · ClinicalTrials.gov ↗ · Solid Tumor
Phase 1 Recruiting 2024-01 China
Effects of Different Inhaled Oxygen Concentrations on Lung Function in Older Patients After Laparoscopic Gastrointestinal Surgery Under General Anesthesia
NCT06359106 · ClinicalTrials.gov ↗ · Oxygenation Index
Phase 4 Recruiting 2024-07 China
Health Behavior Change in High-Risk Colorectal Cancer Individuals
NCT07262840 · ClinicalTrials.gov ↗ · Health Behavior, Colorectal Neoplasms, Primary Prevention/Methods
Not applicable Recruiting 2025-11 China
A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status
NCT07034391 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Phase 2 Recruiting 2025-05 China
Effects of Different Occlusion Angles of Disposable Tracheal Blocker on Right One-lung Ventilation
NCT06595043 · ClinicalTrials.gov ↗ · The Direction of Blocker Placement
Not applicable Recruiting 2024-10 China
The Effect of Situation Puzzle Games on Nursing Students' Death Anxiety and Meaning in Life
NCT06991621 · ClinicalTrials.gov ↗ · Death Anxiety
Not applicable Recruiting 2025-04 China
A Prospective, Single-Arm, Single-Center Phase II Study Evaluating the Efficacy and Safety of Chidamide Combined With PD-L1 Inhibitor, Carboplatin, and Etoposide as First-Line Treatment in Patients With Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)
NCT07373964 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
Phase 2 Recruiting 2025-10 China
Auricular Acupressure for Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Highly Emetogenic Chemotherapy
NCT07760766 · ClinicalTrials.gov ↗ · Chemotherapy-induced Nausea and Vomiting
Not applicable Not yet open 2026-09 China
Prospective, Single-arm, Phase II Clinical Study of Irinotecan Hydrochloride Liposome Injection Combined With Platinum and Immune Checkpoint Inhibitors Combined With Anlotinib for the Maintenance of Extensive Small Cell Lung Cancer After First-line Induction
NCT06951841 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer
Phase 4 Not yet open 2025-04 China
Effects of Adaptive Difficulty Computerized Cognitive Training on Cognitive Function Improvement in Older Adults With Mild Cognitive Impairment
NCT07753382 · ClinicalTrials.gov ↗ · Cognitive Dysfunction, Cognitive Disorder, Cognitive Training
Not applicable Not yet open 2026-08 China
Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations
NCT06118658 · ClinicalTrials.gov ↗ · Gastric, Colorectal Adenocarcinoma
Phase 2 Not yet open 2023-11 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in China Medical University, China trials

2 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in China Medical University, China trials

20 conditions
Small Cell Lung Cancer2Chemotherapy-induced Nausea and Vomiting1Cachexia; Cancer; Sarcopenia1Hypertension1Dyslipidemia1Diabetes1Mild Cognitive Impairment1Cognitive Function1Solid Tumor1Oxygenation Index1Health Behavior1Colorectal Neoplasms1Primary Prevention/Methods1Cognitive Dysfunction, Cognitive Disorder1Cognitive Training1Non-Small Cell Lung Cancer1The Direction of Blocker Placement1Death Anxiety1Gastric1Colorectal Adenocarcinoma1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1410

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Small Cell Lung Cancer

SponsorTrials
Suzhou Zelgen Biopharmaceuticals5
Amgen4
Hangzhou DAC Biotechnology2
Nerviano Medical Sciences1
Han Xu, M.D., Ph.D., FAPCR, Medical Director,, IRB Chair1
Yunpeng Liu1
Heronova Pharmaceuticals1
Tianjin First Central Hospital1

Sponsors with the most current trials registered for this condition.

06

Questions about China Medical University, China trials

How many clinical trials does China Medical University, China sponsor?

China Medical University, China is the lead sponsor of 14 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are China Medical University, China trials recruiting?

Yes. 10 of its 14 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is China Medical University, China testing?

Its current trials name 2 drugs and biologicals as interventions. The most frequent are Tislelizumab (2) and Anlotinib (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.